CN117263940A - Fgfr抑制剂及其制备方法、药物组合物和应用 - Google Patents
Fgfr抑制剂及其制备方法、药物组合物和应用 Download PDFInfo
- Publication number
- CN117263940A CN117263940A CN202210667176.7A CN202210667176A CN117263940A CN 117263940 A CN117263940 A CN 117263940A CN 202210667176 A CN202210667176 A CN 202210667176A CN 117263940 A CN117263940 A CN 117263940A
- Authority
- CN
- China
- Prior art keywords
- pyrrolo
- amino
- phenyl
- pyrimidine
- methoxybenzenesulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 title claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 50
- 108091008794 FGF receptors Proteins 0.000 claims abstract description 27
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 5
- -1 3-dihydrobenzo [1,4] dioxanyl Chemical group 0.000 claims description 104
- 125000000217 alkyl group Chemical group 0.000 claims description 76
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 65
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 49
- 229910052799 carbon Inorganic materials 0.000 claims description 38
- 238000006467 substitution reaction Methods 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 125000002883 imidazolyl group Chemical group 0.000 claims description 14
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000002950 monocyclic group Chemical group 0.000 claims description 12
- 125000003386 piperidinyl group Chemical group 0.000 claims description 12
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 125000000335 thiazolyl group Chemical group 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 239000007858 starting material Substances 0.000 claims description 9
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 8
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 8
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 229910052721 tungsten Inorganic materials 0.000 claims description 6
- 229910052720 vanadium Inorganic materials 0.000 claims description 5
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 229910052770 Uranium Inorganic materials 0.000 claims description 4
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000005917 acylation reaction Methods 0.000 claims description 4
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 230000026030 halogenation Effects 0.000 claims description 4
- 238000005658 halogenation reaction Methods 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 2
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 229940125890 compound Ia Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 229960002510 mandelic acid Drugs 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004838 phosphoric acid Drugs 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- KGRPHHFLPMPUBB-UHFFFAOYSA-N pyrrolo[2,1-f][1,2,4]triazine Chemical class C1=NC=NN2C=CC=C21 KGRPHHFLPMPUBB-UHFFFAOYSA-N 0.000 claims description 2
- 229940107700 pyruvic acid Drugs 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 229940032330 sulfuric acid Drugs 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- 125000005605 benzo group Chemical group 0.000 claims 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 11
- 210000001853 liver microsome Anatomy 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 238000001308 synthesis method Methods 0.000 abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 21
- 239000007787 solid Substances 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 3
- BUMGQSCPTLELLS-UHFFFAOYSA-N 2-chloro-5-nitrophenol Chemical compound OC1=CC([N+]([O-])=O)=CC=C1Cl BUMGQSCPTLELLS-UHFFFAOYSA-N 0.000 description 3
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 3
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 229940121317 pemigatinib Drugs 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IRHIMRCEUXJBGP-UHFFFAOYSA-N 4-(4-nitrophenyl)thiomorpholine Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1CCSCC1 IRHIMRCEUXJBGP-UHFFFAOYSA-N 0.000 description 2
- XORHNJQEWQGXCN-UHFFFAOYSA-N 4-nitro-1h-pyrazole Chemical class [O-][N+](=O)C=1C=NNC=1 XORHNJQEWQGXCN-UHFFFAOYSA-N 0.000 description 2
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 101150088071 fgfr2 gene Proteins 0.000 description 2
- MGZKYOAQVGSSGC-DLBZAZTESA-N fisogatinib Chemical compound COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(N[C@@H]3COCC[C@@H]3NC(=O)C=C)ncc2c1 MGZKYOAQVGSSGC-DLBZAZTESA-N 0.000 description 2
- 229950005712 infigratinib Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- KLOJIPJDBCSTTI-UHFFFAOYSA-N 1,3-benzodioxole-4-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC2=C1OCO2 KLOJIPJDBCSTTI-UHFFFAOYSA-N 0.000 description 1
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 description 1
- KEIPNCCJPRMIAX-HNNXBMFYSA-N 1-[(3s)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound COC1=CC(OC)=CC(C#CC=2C3=C(N)N=CN=C3N([C@@H]3CN(CC3)C(=O)C=C)N=2)=C1 KEIPNCCJPRMIAX-HNNXBMFYSA-N 0.000 description 1
- QKZLSNHQKFSBBJ-UHFFFAOYSA-N 1-chloro-4-nitro-2-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC([N+]([O-])=O)=CC=C1Cl QKZLSNHQKFSBBJ-UHFFFAOYSA-N 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- BKIQORJIKOPRCG-UHFFFAOYSA-N 3-iodooxolane Chemical compound IC1CCOC1 BKIQORJIKOPRCG-UHFFFAOYSA-N 0.000 description 1
- PHNDZBFLOPIMSM-UHFFFAOYSA-N 4-morpholin-4-ylaniline Chemical compound C1=CC(N)=CC=C1N1CCOCC1 PHNDZBFLOPIMSM-UHFFFAOYSA-N 0.000 description 1
- QDMPMBFLXOWHRY-UHFFFAOYSA-N 5-(4-methylpiperazin-1-yl)pyridin-2-amine Chemical compound C1CN(C)CCN1C1=CC=C(N)N=C1 QDMPMBFLXOWHRY-UHFFFAOYSA-N 0.000 description 1
- WSGURAYTCUVDQL-UHFFFAOYSA-N 5-nitro-1h-indazole Chemical class [O-][N+](=O)C1=CC=C2NN=CC2=C1 WSGURAYTCUVDQL-UHFFFAOYSA-N 0.000 description 1
- ORZRMRUXSPNQQL-UHFFFAOYSA-N 6-nitro-1h-indazole Chemical class [O-][N+](=O)C1=CC=C2C=NNC2=C1 ORZRMRUXSPNQQL-UHFFFAOYSA-N 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000012388 BrettPhos 3rd generation precatalyst Substances 0.000 description 1
- LFDGFEUCCQELDJ-UHFFFAOYSA-N COC=1C=C(C=CC=1)C1=C(C=CC=C1)S Chemical compound COC=1C=C(C=CC=1)C1=C(C=CC=C1)S LFDGFEUCCQELDJ-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101150081124 FGFR gene Proteins 0.000 description 1
- 101150025764 FGFR3 gene Proteins 0.000 description 1
- 101150082429 FGFR4 gene Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 230000010558 Gene Alterations Effects 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- XEFCWBLINXJUIV-UHFFFAOYSA-N acetic acid;iodobenzene Chemical compound CC(O)=O.CC(O)=O.IC1=CC=CC=C1 XEFCWBLINXJUIV-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- REWLCYPYZCHYSS-UHFFFAOYSA-N ditert-butyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C(C)(C)C)C(C)(C)C REWLCYPYZCHYSS-UHFFFAOYSA-N 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229950004444 erdafitinib Drugs 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 101150016624 fgfr1 gene Proteins 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 229940121561 fisogatinib Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940121446 futibatinib Drugs 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- OLAHOMJCDNXHFI-UHFFFAOYSA-N n'-(3,5-dimethoxyphenyl)-n'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-n-propan-2-ylethane-1,2-diamine Chemical compound COC1=CC(OC)=CC(N(CCNC(C)C)C=2C=C3N=C(C=NC3=CC=2)C2=CN(C)N=C2)=C1 OLAHOMJCDNXHFI-UHFFFAOYSA-N 0.000 description 1
- TWXOILOJQLTRJY-UHFFFAOYSA-N n,n-dimethyl-2-(4-nitropyrazol-1-yl)ethanamine Chemical compound CN(C)CCN1C=C([N+]([O-])=O)C=N1 TWXOILOJQLTRJY-UHFFFAOYSA-N 0.000 description 1
- BHCKWNCABQSFOK-UHFFFAOYSA-N n,n-dimethyl-2-(5-nitroindazol-1-yl)ethanamine Chemical compound [O-][N+](=O)C1=CC=C2N(CCN(C)C)N=CC2=C1 BHCKWNCABQSFOK-UHFFFAOYSA-N 0.000 description 1
- KKPFRVYFQYRWSC-UHFFFAOYSA-N n,n-dimethyl-2-(6-nitroindazol-1-yl)ethanamine Chemical compound C1=C([N+]([O-])=O)C=C2N(CCN(C)C)N=CC2=C1 KKPFRVYFQYRWSC-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
本发明公开了一类FGFR抑制剂及其制备方法、药物组合物和应用。其化合物结构如式I,还包含其立体异构体、药学上可接受的盐或它们的混合物。该类FGFR抑制剂及其药物组合物对野生型及突变型FGFR具有高效的抑制作用,可用于制备与FGFR相关疾病的药物,所制备药物在分子水平和细胞水平均可以发挥药效,应用广泛,并且具有优异的肝微粒体稳定性,体内半衰期长,生物利用度高,具有较好的类药性质。此外,该类化合物合成方法简便,易操作。
Description
技术领域
本发明涉及一种FGFR抑制剂及其制备方法、药物组合物和应用,尤其涉及一种对耐药突变体FGFRV550L具有优异的特异性抑制活性的FGFR抑制剂及其制备方法、药物组合物和应用。
背景技术
成纤维细胞生长因子受体(FGFR)属于受体酪氨酸激酶(RTKs)家族。通过与其配体结合,即成纤维细胞生长因子(FGF),FGFR可以在细胞膜上形成一个同源二聚体。这些二聚体可引起FGFR胞内关键酪氨酸残基的磷酸化,从而激活细胞内的一些下游信号传导通路。这些细胞内信号通路在细胞增殖、生存和分化中发挥着重要作用。FGFR信号转导途径的紊乱,包括配体和受体的表达增加、FGFR基因扩增和突变、缺失等改变,可以促进细胞的致癌转化,在肿瘤细胞增殖、耐药和血管生成中发挥重要作用。例如,在30%的肝癌中发现了FGFR4基因的扩增;在10%-20%的胆管癌发现了FGFR2基因的融合;在10%-60%的尿路上皮癌中发现了FGFR3基因的突变;在10%的非小细胞肺癌(NSCLC)中发现了FGFR1基因的扩增等改变等。由于FGFR在肿瘤的发生和发展过程中起着关键性的作用,开发新的具有高抑制活性和优异药代动力学性质的FGFR激酶抑制剂已成为开发新型抗肿瘤药物的关键。
截至目前,仅有三款靶向FGFR的小分子抑制剂(Erdafitinib、Infigratinib和Pemigatinib)上市,多款小分子抑制剂临床在研(如Futibatinib、Fisogatinib等)。临床试验表明,FGFR4选择性抑制剂Fisogatinib(BLU-554)对FGF19过表达的患者显示出了临床效益和肿瘤发生消退。Pemigatinib被美国FDA批准用于既往接受过治疗的携带FGFR2融合/重排的局部晚期或转移性胆管癌患者。Infigratinib被美国FDA批准用于既往接受过治疗且携带FGFR2基因融合或其它重排类型的不可切除局部晚期或转移性胆管癌成人患者。
尽管FGFR是经验证的治疗的癌症药物靶点和生物标志物,但是在上述药物在临床应用中存在一定比例的耐药现象。患者在使用Fisogatinib抑制剂治疗6个月后,观察到有29%的患者对这些小分子抑制剂的抗性。FGFR4耐药突变的频率与非小细胞肺癌中的EGFR和ALK突变的频率相当。其中最突出的耐药突变是门卫残基V550L和V550M。这种获得性突变极大降低了药物与靶点的亲和力,从而产生耐药性,并导致肿瘤复发或疾病进展。同样Pemigatinib与Infigratinib都存在门卫残基突变,产生获得性耐药的问题。
发明内容
发明目的:针对现有化合物对门卫残基发生突变的FGFR亚型抑制活性不足等问题,本发明旨在提供一种针对耐药突变体FGFRV550L具有显著特异性抑制作用的FGFR抑制剂及其制备方法、药物组合物和应用。
技术方案:作为本发明涉及的第一方面,本发明的FGFR抑制剂具有式I的结构,所述FGFR抑制剂包含其立体异构体、药学上可接受的盐或它们的混合物:
其中,U选自CH或N;
V、W各自独立地选自C或N且不相同;
X选自O、NH、NCH3、NCN或NCF3;
Y选自N或C;
Z选自N或CH;
A环选自芳基或芳杂基;所述芳基选自苯基、萘基、苊基或四氢萘基;所述芳杂基选自哌啶基、吡咯基、吡唑基、咪唑基、呋喃基、噻吩基、噁唑基、异噁唑基、噻唑基、异噻唑基、吡啶基、嘧啶基、吡嗪基、哒嗪基、喹啉基、喹唑啉基、吲哚基、苯并咪唑基、苯并噁唑基、苯并异噁唑基、苯并噻唑基、苯并异噻唑基、苯并呋喃基、苯并噻吩基、2,3-二氢苯并[1,4]二氧杂环己烯基或苯并[1,3]二氧杂环戊烯基;
R1、R2、R3、R4、R6各自独立地选自H、卤素、CH2OH、CF3、OCF3、CN、C1-6烷基或C1-6烷氧基;或者R2、R3连接在一起形成3-8元杂环,所述3-8元杂环可任选地被C1-6烷基取代;
R5选自-ORa、-(CH2)mORa、-NRaRb、-CONRaRb、-SO2NRaRb、-(SONH)NRaRb、-(CH2)m-NRaRb、-(CH2)mCON(CH3)2、-(CH2)mSO2N(CH3)2或3-10元杂环,所述3-10元杂环可任选地被1-3个R7取代;m=1、2或3;
Ra、Rb各自独立地选自H、C1-6烷基、-COC1-5烷基或-SO2C1-5烷基,所述C1-6烷基、-COC1-5烷基、-SO2C1-5烷基任选地被-NRcRd、-CONRcRd或-SO2C1-5烷基取代;
Rc、Rd各自独立地选自H、C1-6烷基或-COC1-5烷基;
R7选自C1-6烷基、C3-8环烷基、-CONH2、-SO2NH2、-CH2COOH、-CH2SO3H、-CH2CN、-(CH2)2NRcRd、-NRcRd、-(CH2)nOH、-COOC1-6烷基或3-8元杂环,所述3-8元杂环可任选地被C1-6烷基取代;n=1、2或3。
进一步地,上述FGFR抑制剂具有式IA或IB的结构:
其中A、X、Y、Z、R1~R6的定义如权利要求1所述。
优选,上述结构中:
X选自O或NH;
Y选自N或C;
Z选自N或CH;
A环选自芳基或芳杂基;所述芳基选自苯基、萘基、苊基或四氢萘基;所述芳杂基选自哌啶基、吡咯基、吡唑基、咪唑基、呋喃基、噻吩基、噁唑基、异噁唑基、噻唑基、异噻唑基、吡啶基、嘧啶基、吡嗪基、哒嗪基、喹啉基、喹唑啉基、吲哚基、苯并咪唑基、苯并吡唑基、苯并异噁唑基、苯并噻唑基、苯并异噻唑基、苯并呋喃基、苯并噻吩基、2,3-二氢苯并[1,4]二氧杂环己烯基或苯并[1,3]二氧杂环戊烯基;
R1、R2各自独立地选自H、卤素、CN或C1-6烷氧基;
R3、R4各自独立地选自H、卤素、OCF3或C1-6烷氧基;或者R2、R3连接在一起形成5-6元单环烷基或5-6元单环芳杂基;所述5-6元单环烷基选自四氢呋喃基、吡咯烷基、1,3-二噁茂基、1,3-噁唑烷基或哌啶基;所述5-6元单环芳杂基选自哌啶基、吡咯基、吡唑基、咪唑基、呋喃基、噻吩基、噁唑基、异噁唑基、噻唑基、异噻唑基、吡啶基、嘧啶基、吡嗪基或哒嗪基;
R6选自H、卤素、CH2OH、C1-6烷基或C1-6烷氧基;
R5选自-ORa、-(CH2)mORa、-NRaRb、-CONRaRb、-SO2NRaRb、-(SONH)NRaRb、-(CH2)m-NRaRb、-(CH2)mCON(CH3)2、-(CH2)mSO2N(CH3)2或3-10元杂环,所述3-10元杂环可任选地被1-3个R7取代;m=1、2或3;
Ra、Rb各自独立地选自H、C1-6烷基、-COC1-5烷基或-SO2C1-5烷基,所述C1-6烷基、-COC1-5烷基、-SO2C1-5烷基任选地被-NRcRd、-CONRcRd或-SO2C1-5烷基取代;
Rc、Rd各自独立地选自H、C1-6烷基或-COC1-5烷基;
R7选自C1-6烷基、C3-8环烷基、-CONH2、-SO2NH2、-CH2COOH、-CH2SO3H、-CH2CN、-(CH2)2NRcRd、-NRcRd、-(CH2)nOH、-COOC1-6烷基或3-8元杂环,所述3-8元杂环任选地被C1-6烷基取代;n=1、2或3。
进一步优选,上述结构中:
X选自O;
Y选自N或C;
Z选自N或CH;
A环选自苯基、吡唑基、咪唑基、吡啶基、嘧啶基、苯并咪唑基、苯并吡唑基或苯并异噁唑基;
R1、R2各自独立地选自H、F、Cl、CN或C1-3烷氧基;
R3、R4各自独立地选自H、F、Cl或C1-3烷氧基;或者R2、R3连接在一起形成5-6元单环烷基或5-6元单环芳杂基;所述5-6元单环烷基选自1,3-二噁茂基、1,3-噁唑烷基或哌啶基;所述5-6元单环芳杂基选自吡唑基、咪唑基、异噁唑基或噻唑基;
R6选自H、F、Cl或C1-3烷氧基;
R5选自-ORa、-(CH2)mORa、-NRaRb、-CONRaRb、-SO2NRaRb、-(SONH)NRaRb、-(CH2)m-NRaRb、-(CH2)mCON(CH3)2、-(CH2)mSO2N(CH3)2或3-10元杂环,所述3-10元杂环可任选地被1-3个R7取代;m=1、2或3;
Ra、Rb各自独立地选自H、C1-6烷基、-COC1-5烷基或-SO2C1-5烷基,所述C1-6烷基、-COC1-5烷基、-SO2C1-5烷基任选地被-NRcRd、-CONRcRd或-SO2C1-5烷基取代;
Rc、Rd各自独立地选自H、C1-6烷基或-COC1-5;
R7选自C1-6烷基、C3-8环烷基、-CONH2、-SO2NH2、-CH2COOH、-CH2SO3H、-CH2CN、-(CH2)2NRcRd、-NRcRd、-(CH2)nOH、-COOC1-6烷基或3-8元杂环,所述3-8元杂环任选地被C1-6烷基取代;n=1、2或3。
更进一步优选,上述结构中:
X选自O;
Y选自N或C;
Z选自N或CH;
A环选自苯基、吡唑基、咪唑基、吡啶基、嘧啶基、苯并咪唑基、苯并吡唑基或苯并异噁唑基;
R1、R2各自独立地选自H、F、Cl、CN或C1-3烷氧基;
R3、R4各自独立地选自H、F、Cl或C1-3烷氧基;或者R2、R3连接在一起形成5-6元单环烷基或5-6元单环芳杂基;所述5-6元单环烷基选自1,3-二噁茂基、1,3-噁唑烷基或哌啶基;所述5-6元单环芳杂基选自吡唑基、咪唑基、异噁唑基或噻唑基;
R6选自H、F、Cl或C1-3烷氧基;
R5选自
最优选,上述的FGFR抑制剂选自下列任一化合物:
/>
上述FGFR抑制剂药学上可接受的盐包括通式I化合物与下列酸形成的盐:盐酸、氢溴酸、硫酸、磷酸、甲磺酸、苯磺酸、对甲苯磺酸、萘磺酸、拧檬酸、酒石酸、乳酸、丙酮酸、乙酸、马来酸或琥珀酸、富马酸、水杨酸、苯基乙酸、杏仁酸;还包括通式I化合物与下列碱形成的盐:碱性金属阳离子盐、碱土金属阳离子盐或铵阳离子盐。
作为本发明涉及的第二方面,上述FGFR抑制剂的制备方法选自下列任一方法:
(1)当U、W为N,V为C时,以溴代苯或溴代吡啶为起始原料,经过取代、卤代、酰化反应制备而成通式化合物IA,
(2)当U、W为N,V为C时,以溴代苯或溴代吡啶为起始原料,经过取代、卤代、酰化、取代反应制备而成通式化合物IA,
(3)当U、V为N,W为C时,卤代吡咯并[2,1-f][1,2,4]三嗪为起始原料,经过两步取代、氧化、反应制备而成通式化合物IB,
其中,Y、Z、R1~R6的定义如前所述;
将上述方法制备而成的化合物IA或IB与相应的酸或碱成盐,即得其药学上可接受的盐。
作为本发明涉及的第三方面,上述FGFR抑制剂与药学上可接受的载体形成药物组合物,具体的制剂形式如片剂、胶囊、糖浆、悬浮剂或注射剂,制剂可以加入香料、甜味剂、液体/固体填料、稀释剂等常用药用辅料。
作为本发明涉及的第四方面,上述FGFR抑制剂及其药物组合物应用于制备预防和/或治疗FGFR相关疾病的药物,具体为预防和/或治疗肝癌、非小细胞肺癌、胃癌、膀胱癌、头颈癌、胆管癌、乳腺癌、子宫内膜癌、***、食道癌、肾癌、急性白血病、***癌、甲状腺癌、皮肤癌、结肠直肠癌、胰腺癌、卵巢癌、骨髓增生异常综合症或间皮瘤的药物。
有益效果:与现有技术相比,本发明具有如下显著优点:
(1)该类FGFR抑制剂及其药物组合物可有效抑制野生型FGFR、突变型FGFR4V550L和HUH7细胞增殖,IC50值最优均低于50nM;
(2)该类FGFR抑制剂及其药物组合物具有优异的肝微粒体稳定性,体内半衰期长、清除率低,生物利用度高,AUC合适,具有较好的类药性质;
(3)该类FGFR抑制剂及其药物组合物应用广泛,可制备为治疗和/或预防与FGFR相关疾病的药物,尤其适用于对常规FGFR抑制剂耐药的各种肿瘤;所述药物在分子水平和细胞水平均可以发挥药效,并且治疗效果更优异,最优可达到十纳摩尔浓度级别水平;
(4)化合物制备方法简便、易操作。
附图说明
图1为化合物I-63的小鼠体内代谢结果。
具体实施方式
下面结合实施例对本发明的技术方案作进一步说明。
本发明具体实施例中使用的起始原料、反应试剂等均为市售。本发明可以采用本领域常用的成盐方法制备成盐的形式,例如:室温下,将化合物溶于盐酸乙醇中进行反应,生成盐酸盐;或者向其中加入苯磺酸进行反应生成苯磺酸盐。
实施例1:4-苄硫基苯并[d][1,3]二噁茂(I-26-2)
将4-溴苯并[d][1,3]二噁茂(I-26-1)(402mg,2mmol)、苄硫醇(298mg,2.4mmol)、LiHMDS(1M,3mL)和tBuBrettPhos Pd G3(20mg)悬浮于1,4-二氧六环(10mL),氮气氛下加热至85℃,反应2小时。旋干反应液,通过柱层析得白色固体361mg。[M+H]+:245.3。1H NMR(300MHz,Chloroform-d)δ7.35–7.21(m,5H),6.81–6.73(m,3H),5.99(s,2H),4.13(s,2H).
采用与实施例1相似的操作,制得下列化合物:
实施例2:苯并[d][1,3]二噁茂-4-磺酰氯(I-26-3)
将4-苄硫基苯并[d][1,3]二噁茂(I-26-2)(488mg,2mmol)溶于乙腈与醋酸(3:1)的混合溶剂中,向其中缓慢加入NCS(1.07g,8mmol)。搅拌2小时后,加入碳酸氢钠水溶液。用乙酸乙酯萃取,柱层析得无色液体352mg。[M+H]+:221.62
采用与实施例2相似的操作,制得下列化合物:
实施例3:N-(4-吗啉苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-1-5)
将6-氯-1H-吡咯并[3,2-c]吡啶(307mg,2mmol)、4-吗啉苯胺(356mg,2mmol)与对甲苯磺酸(1.03g,6mmol)悬浮于正丁醇(6mL)中。封管,在140℃下反应24h。将反应液冷却至室温,向其中加入二氯甲烷(20mL)和饱和碳酸氢钠水溶液(20mL)。搅拌,抽滤,干燥滤饼,得白色固体237mg。[M+H]+:296.35。1H NMR(300MHz,Chloroform-d)δ9.71(d,J=8.3Hz,1H),8.92(dd,J=2.2,0.5Hz,1H),7.74–7.59(m,3H),7.03–6.93(m,2H),6.62(dd,J=6.5,2.2Hz,1H),5.80(s,1H),3.86(dd,J=7.5,4.8Hz,4H),3.16(dd,J=7.6,4.9Hz,4H).
采用与实施例3相似的操作,制得下列化合物:
实施例4:N-(4-吗啉苯基)-7-苯磺酰基-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-1)
将N-(4-吗啉苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-1-5)(295mg,1mmol)溶解于DMF(3mL)中,冰浴下分批加入氢化钠(60%,48mg,1.5mmol)。当不再有气泡产生时,缓慢加入苯磺酰氯(I-1-4)(265mg,1.5mmol)。反应2小时后,将反应液倒入冰水中搅拌,乙酸乙酯萃取。乙酸乙酯层经过整层析纯化得白色固体191mg。[M+H]+:436.50。1H NMR(300MHz,DMSO)δ9.57(s,1H),8.70(s,1H),8.19–8.01(m,2H),7.77–7.66(m,3H),7.64–7.52(m,3H),6.98(d,J=9.1Hz,2H),6.72(d,J=4.0Hz,1H),3.77(dd,J=6.0,3.6Hz,4H),3.14–3.03(m,4H).
采用与实施例4相似的操作,制得下列化合物:
/>
/>
实施例5:3-(2-氯-5-硝基苯氧基)四氢呋喃(I-41-8)
将2-氯-5-硝基苯酚(347mg,2mmol)溶解于DMF(4mL)中,冰浴下缓慢加入氢化钠(60%,96mg,4mmol),搅拌30分钟后,加入3-碘四氢呋喃(594mg,3mmol),反应结束后,加入饱和氯化铵水溶液淬灭反应,乙酸乙酯萃取,经柱层析纯化,得黄色固体428mg。[M+H]+:244.64。
采用与实施例5相似的操作,制得下列化合物:
化合物 | 原料 | ESI-MS m/z |
1-氯-2-异丙氧基-4-硝基苯(I-42-8) | 2-氯-5-硝基苯酚 | 216.63 |
4-(2-(2-氯-5-硝基苯氧基)乙基)吗啉(I-47-8) | 2-氯-5-硝基苯酚 | 287.71 |
N,N-二甲基-2-(5-硝基-1H-吲唑-1-基)乙胺(I-48-8) | 5-硝基-2H-吲唑 | 235.11 |
N,N-二甲基-2-(6-硝基-1H-吲唑-1-基)乙胺(I-49-8) | 6-硝基-2H-吲唑 | 235.11 |
N,N-二甲基-2-(4-硝基-1H-吡唑-1-基)乙胺(I-57-8) | 4-硝基-1H-吡唑 | 185.1 |
N,N-二甲基-3-(4-硝基-1H-吡唑-1-基)丙胺(I-58-8) | 4-硝基-1H-吡唑 | 189.11 |
实施例6:N1-(2-(二甲基氨基)乙基)-N1-甲基-1,4-苯二胺(I-14-7)
第一步,将对氟硝基苯(282mg,2mmol),3-甲基-1-(哌嗪基)氮杂环丁-3-醇(1.7g,10mmol)溶解于乙腈(10mL)中,加热至80℃反应。反应完成后,旋干反应液,通过柱层析纯化,得到黄色固体中间体。第二步,将该固体溶解于乙醇(10mL)中,加入钯/炭催化剂,常压氢化。反应完成后,抽滤旋干得灰色油状物440mg。[M+H]+:263.35。
采用与实施例6相似的操作,制得下列化合物:
化合物 | ESI-MS m/z | 化合物 | ESI-MS m/z |
I-17-7 | 275.41 | I-57-7 | 155.21 |
I-37-7 | 262.36 | I-58-7 | 169.24 |
I-38-7 | 262.36 | I-61-7 | 218.31 |
I-39-7 | 275.41 | I-63-7 | 206.3 |
I-41-7 | 278.36 | I-66-7 | 318.43 |
I-42-7 | 250.35 | I-72-7 | 290.37 |
I-43-7 | 206.30 | I-75-7 | 206.26 |
I-44-7 | 206.3 | I-78-7 | 304.4 |
I-47-7 | 321.43 | I-86-7 | 318.43 |
I-48-7 | 205.27 | I-88-7 | 192.23 |
I-49-7 | 205.27 | I-90-7 | 206.3 |
I-56-7 | 207.28 | I-92-7 | 231.31 |
实施例7:7-(3-甲氧基苯磺酰基)-N-(5-(4-甲基哌嗪)吡啶-2-基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-9)
将2-氯-7-(3-甲氧基苯磺酰基)-7H-吡咯并[2,3-d]嘧啶(I-2-6)(324mg,1mmol)、1-甲基-4-(6-氨基吡啶-3-基)哌嗪(193mg,1mmol)与对甲苯磺酸(1.03g,3mmol)悬浮于异丙醇(3mL)中。封管,在130℃下反应24h。将反应液冷却至室温,加入饱和碳酸氢钠中和反应液,乙酸乙酯萃取,旋干通过柱层析得到黄色固体254mg。[M+H]+:480.55。1H NMR(300MHz,Chloroform-d)δ8.73(s,1H),8.68–8.64(m,1H),8.59(s,1H),8.16–8.08(m,1H),7.72(dd,J=2.6,1.7Hz,1H),7.66(ddd,J=7.8,1.8,1.0Hz,1H),7.50(dd,J=9.2,3.0Hz,1H),7.44(d,J=4.0Hz,1H),7.34(t,J=8.1Hz,1H),7.08(ddd,J=8.4,2.6,1.0Hz,1H),6.55(d,J=4.0Hz,1H),3.59(s,3H),3.32–3.20(m,4H),2.67(dd,J=6.2,3.8Hz,4H),2.41(s,3H).采用与实施例7相似的操作,制得下列化合物:
/>
/>
/>
实施例8:N-(4-(2,7-二氮杂物[3.5]壬烯-7-基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-66)
将2-氯-7-(3-甲氧基苯磺酰基)-7H-吡咯并[2,3-d]嘧啶(I-2-6)(323mg,1mmol)、7-(4-氨基苯基)-2,7-二氮杂螺[3.5]壬烷-2-甲酸叔丁酯(I-2-7)(380mg,1.2mmol)、碳酸铯(538mg,1.5mmol)和BrettPhos Pd G3(20mg)悬浮于1,4-二氧六环(8mL),氮气氛下加热至90℃,反应2小时。旋干反应液,通过柱层析得到偶联产物。将该固体溶解于盐酸溶液(3M甲醇溶液,5mL),搅拌30分钟后,旋干,溶解于甲醇(5mL)中,加入碳酸钾中和。抽滤旋干甲醇溶液得黄色固体252mg。[M+H]+:505.6。1H NMR(300MHz,Chloroform-d)δ9.70(s,1H),8.79(dd,J=2.2,0.5Hz,1H),8.32–8.24(m,1H),8.04(ddd,J=8.3,1.9,1.2Hz,1H),7.86(dd,J=8.5,2.3Hz,1H),7.50(t,J=1.9Hz,1H),7.39(dd,J=8.4,7.8Hz,1H),7.30–7.20(m,2H),6.99–6.85(m,3H),3.79(s,3H),3.47(dd,J=7.9,5.1Hz,2H),3.29(dd,J=7.9,5.2Hz,2H),2.87(d,J=5.4Hz,2H),2.73(d,J=5.5Hz,2H),2.28(p,J=5.4Hz,1H),1.81(ddd,J=9.7,7.9,5.1Hz,4H).
采用与实施例8相似的操作,制得下列化合物:
实施例9:7-(3-甲氧基苯磺酰基)-N-(4-(2-甲基-2,7-二氮杂螺[3.5]壬烯-7-基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-68)
将N-(4-(2,7-二氮杂物[3.5]壬烯-7-基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-66)(252mg,0.5mmol)和碳酸钾(138mg,1mmol)悬浮于乙腈(3mL)中,加入碘甲烷(142mg,1mmol)搅拌,反应结束后,旋干反应液,通过柱层析纯化得黄色固体217mg。[M+H]+:519.63。1H NMR(300MHz,Chloroform-d)δ9.70(s,1H),8.79(dd,J=2.2,0.5Hz,1H),8.32–8.24(m,1H),8.04(ddd,J=8.3,1.9,1.2Hz,1H),7.88(dd,J=8.4,2.2Hz,1H),7.50(t,J=1.9Hz,1H),7.39(dd,J=8.5,7.8Hz,1H),7.30–7.20(m,2H),7.01–6.85(m,3H),3.79(s,3H),3.47(dd,J=8.1,5.5Hz,2H),3.38(dd,J=8.1,5.4Hz,2H),2.76(d,J=10.9Hz,2H),2.68(d,J=10.9Hz,2H),2.32(s,3H),1.79(dd,J=8.1,5.3Hz,4H).
采用与实施例9相似的操作,制得下列化合物:
/>
实施例10:4-(4-硝基苯基)硫代吗啉(I-94-13)
以硫代吗啉为原料,依照实施例5第一步的合成方法同比例投料,得黄色固体316mg。[M+H]+:225.28。1H NMR(300MHz,Chloroform-d)δ8.09–7.99(m,1H),7.06–6.96(m,1H),3.72(dd,J=7.3,4.6Hz,2H),2.95(dd,J=7.2,4.5Hz,2H).
实施例11:1-亚氨基-4-(4-硝基苯基)-1λ6-硫代吗啉-1-氧化物(I-94-14)
将4-(4-硝基苯基)硫代吗啉(I-94-13)(224mg,1mmol)和碳酸铵(644mg,2mmol),溶解于四氢呋喃(5mL)中,降温至0℃。再缓慢加入碘苯二乙酸(192mg,2mmol),反应2小时后,旋干反应液,柱层析得到黄色固体173mg。[M+H]+:256.29。1H NMR(300MHz,Chloroform-d)δ8.09–7.99(m,1H),7.06–6.96(m,1H),3.23(ddd,J=10.2,7.6,0.6Hz,2H),2.80(ddd,J=10.2,7.4,0.6Hz,2H).
实施例12:(4-(4-氨基苯基)-1-氧代-1λ6-硫代吗啉-1-亚基)氨基甲酸叔丁酯(I-94-7)
将1-亚氨基-4-(4-硝基苯基)-1λ6-硫代吗啉-1-氧化物(I-94-14)(225mg,1mmol)溶解于四氢呋喃(5mL)中,降温至-78℃。再缓慢滴加LiHMDS(1M,2mL),搅拌30分钟。再向其中加入二碳酸二叔丁酯(260mg,1.2mmol)。反应2小时后,将反应液升至常温,加入氯化铵饱和溶液,乙酸乙酯萃取,柱层析得到黄色固体。再将该固体依照实施例6第二步的合成方法同比例投料,得灰色油状物300mg。[M+H]+:356.41。1H NMR(300MHz,Chloroform-d)δ8.09–7.99(m,2H),7.06–6.96(m,2H),3.23(ddd,J=10.5,7.8,0.6Hz,4H),2.80(ddd,J=10.5,7.8,0.6Hz,4H),1.44(s,9H).
实施例13:1-亚氨基-4-(4-((7-(3-甲氧基苯磺酰基)-7H-吡咯并[2,3-d]嘧啶-2-基)氨基)苯基)-1λ6-硫代吗啉-1-氧化物(I-94)
以(4-(4-氨基苯基)-1-氧代-1λ6-硫代吗啉-1-亚基)氨基甲酸叔丁酯(I-94-7)与2-氯-7-(3-甲氧基苯磺酰基)-7H-吡咯并[2,3-d]嘧啶(I-2-6)为原料,依照实施例8的合成方法同比例投料,得白色固体217mg。[M+H]+:513.13。1H NMR(300MHz,Chloroform-d)δ9.49(s,1H),9.20(s,1H),8.79(dd,J=2.2,0.5Hz,1H),8.32–8.24(m,1H),8.01(ddd,J=8.5,1.9,1.1Hz,1H),7.86(dd,J=8.5,2.3Hz,1H),7.51(t,J=1.9Hz,1H),7.39(dd,J=8.5,7.8Hz,1H),7.30–7.20(m,2H),7.04–6.90(m,3H),3.79(s,3H),3.67(dd,J=10.3,7.6Hz,4H),2.82(ddd,J=10.1,7.6,2.4Hz,4H).
实施例14:7-(3-甲氧基苯硫基)-N-(4-(4-甲基哌嗪苯基))-2-氨基吡咯并[2,1-f][1,2,4]三嗪(I-64-12)
将7-溴-2-氨基-N-(4-(4-甲基哌嗪苯基))吡咯并[2,1-f][1,2,4]三嗪(I-64-10)(387mg,1mmol)、3-甲氧基苯硫酚(I-64-11)(280mg,2mmol)、碘化亚铜(20mg,0.1mmol)、乙二醇(0.3mL)与磷酸钾(637mg,3mmol)悬浮于DMF(6mL)中。封管,在120℃下反应48h。将反应液冷却至室温,倒入水中,用乙酸乙酯萃取,旋干乙酸乙酯层,柱层析得到黄色固体311mg。[M+H]+:447.57。1H NMR(300MHz,CDCl3)δ8.68(s,1H),7.39–7.29(m,2H),7.17(t,J=8.0Hz,1H),6.93(d,J=4.6Hz,1H),6.87–6.67(m,7H),3.74(s,3H),3.20(dd,J=6.7,3.5Hz,4H),2.77–2.57(m,4H),2.41(s,3H).
实施例15:7-(3-甲氧基苯磺酰基)-N-(4-(4-甲基哌嗪苯基))-2-氨基吡咯并[2,1-f][1,2,4]三嗪(I-64)
将7-(3-甲氧基苯硫基)-N-(4-(4-甲基哌嗪苯基))-2-氨基吡咯并[2,1-f][1,2,4]三嗪(I-64-12)(223mg,0.5mmol)溶解于甲醇(5mL)中。向其中加入双氧水(30%,1mL)。反应2小时后,向其中加入饱和碳酸氢钠水溶液,再加入饱和硫代硫酸钠水溶液,搅拌30分钟。加入二氯甲烷萃取反应液,旋干二氯甲烷层,柱层析得到黄色固体220mg。[M+H]+:479.58。1HNMR(300MHz,CDCl3)δ8.77(s,1H),7.80–7.42(m,4H),7.34(d,J=4.9Hz,1H),7.27(s,1H),7.10–6.98(m,3H),6.91(s,1H),6.72(d,J=4.9Hz,1H),3.50(s,3H),3.32–3.24(m,4H),2.87–2.57(m,4H),2.43(s,3H).
实施例16:生物学活性
1、激酶IC50测试实验方法
反应阶段:配制assay buffer,稀释化合物;准备5×激酶(终浓度0.3ng/μL、工作浓度1.5ng/μL)with assay buffer,每孔2μL;准备2.5×TK-Substrate-biotin/ATP withassay buffer,ATP终浓度100μM,底物终浓度500nM,每孔4μL;孔中加入4μL化合物with2.5%DMSO,阳性对照孔加入4μL assay buffer with 2.5%DMSO;化合物孔及阳性对照孔中加入4μL 2.5×TK-Substrate-biotin/ATP和2μL 5×FGFR4,无酶阴性对照孔加入4μL2.5×TK-Substrate-biotin/ATP和6μL assay buffer;室温孵育1.0h。
测定阶段:用detection buffer将Sa-XL665(储存浓度16.67μM)稀释至500nM,每孔加5μL;每孔加入5μL TK Antibody-Cryptate;孵育1h;读板。用GraphPad Prism 5.0软件计算各化合物的IC50值。
2、细胞IC50测试实验方法
细胞培养:37℃水浴解冻细胞,冻存管表面喷洒75%酒精后将细胞转移至预先加入10mL培养基的15mL离心管中,1000rpm离心5min。去掉上清后用1mL培养基重悬细胞,后将细胞悬液转移至加入适量培养基的培养皿中,置于37℃,5%CO2培养箱中培养。待细胞汇合度达到90%,对细胞进行传代处理。将培养皿中的培养基去除,然后向培养皿中加入适量0.25%胰酶,置于37℃培养箱,待细胞变圆后取出,向培养皿中加入培养基重悬细胞,重悬的细胞置于15mL离心管中,1000rpm离心5min。用培养基将离心后的进行重悬,1:3-1:5进行传代,置于37℃,5%CO2培养箱中培养。将汇合度达到90%的细胞,用0.25%胰酶进行消化,消化后的细胞悬液进行计数。向384板中分别种20μL(800cell/well)细胞,后将细胞板置于37℃,5%CO2培养箱中培养过夜。
化合物准备:10mM化合物储存溶液用DMSO稀释,制成浓度为2mM的化合物溶液。然后以2mM为起始浓度,用DMSO将化合物进行三倍梯度稀释,总计12个浓度点。
加化合物:将1μL的化合物梯度稀释DMSO溶液加至99μL的完全培养基中,配制成起始溶度为10μM,DMSO溶度为1%的化合物工作溶液。细胞培养过夜后,向细胞板中加入上述配制好的工作溶液20μL/孔。并继续培养72h。
读板:向细胞板中加入20μL/孔的cell Titer-Glo reagent,室温避光反应15min,然后用酶标仪读板。采用prism对数据进行处理,拟合计算出化合物的IC50值。
3、实验结果
表1是部分化合物的体外FGFR激酶活性及体外癌细胞活性测试结果。A代表IC50值小于50nM,B代表IC50值介于50nM至200nM之间,C代表IC50值大于200nM。
表1化合物的体外活性
/>
从表1可见,本发明的2-氨基-7H-吡咯并[2,3-d]嘧啶类化合物对野生型FGFR、突变型FGFRV550L和HUH7细胞增殖均具有抑制作用,IC50值最优均低于50nM,其在分子水平和细胞水平均具有优异的活性,可为制备预防和/或治疗与FGFR相关疾病的药物以及为其它FGFR抑制疗法耐药后的治疗提供依据。
实施例17:药物代谢动力学实验
1、肝微粒体稳定性测试
在多种肝微粒体包括:RLM(大鼠肝微粒体)、DLM(犬肝微粒体)、CLM(猴肝微粒体)和HLM(人肝微粒体)对待测化合物进行代谢稳定性测定。向每个孔(T0、T5、T15、T30、T60和NCF60)中,加入待试化合物溶液或对照药溶液。再向每个孔板中加入80μL微粒体溶液后,将混合物在37℃下孵育10min。在NCF60中,每孔加入10μL 100mM磷酸钾缓冲液,在37℃下孵育1.0h。预热后。利用甲苯磺丁酰胺和拉贝洛尔的混合物(1:1),在孵育后的5,15,30和60min以终止反应。将混合物涡旋5min,在4℃以4000rpm离心20min,并通过LC-MS分析上清液。通过一级动力学分析数据以计算“T1/2”和“CL”。
2、小鼠体内代谢分析实验
取正常小鼠和荷瘤小鼠组各30只,再随机分为6个时间组(2、4、10、15、30、60min),禁食12h,尾静脉给药。各时间组小鼠分别于给药后的预定时间点取血样,处理为血浆备用;然后处死小鼠,取出肝脏和肿瘤组织,匀浆、离心后取上清液备用。取血浆及匀浆上清液,利用LC-MS进行分析,测定组织中的药物及其相关代谢物的含量,绘制药-时曲线(AUC),用药代动力学相关软件进行处理,求出各主要药代动力学参数。考察药物在两组小鼠体内的半衰期、药代动力学参数及组织分布情况,以评价药物的成药性及其在肿瘤组织的靶向性。
选取6只8周左右雄性Sprague-Dawley老鼠禁食一夜之后,开始药物的静脉注射和口服吸收药代动力学测定。为了确定口服生物利用度,以1和10mg/kg的剂量分别通过单次静脉内(IV)快速推注或灌胃给药待试化合物。注射制剂:(DMSO:PEG200:盐水=20:20:60,v/v/v,浓度为0.2mg/mL)。另外,将化合物混悬于含有0.5%CMC-Na和0.2%Tween 80的生理盐水中以获得口服制剂(浓度为1mg/mL)。对于血浆样品:取30μL样品的等分试样加入150μLACN,其中含有5ng/mL的维拉帕米和50ng/mL的格列本脲,用于蛋白质沉淀。将混合物涡旋振荡10min并以3700rpm离心10min。然后,向70μL上清液中加入70μL水,并涡旋10min。将等份的15μL混合物注入***,并使用Agilent Technologies6430LC-MS***进行LC-MS/MS分析。
3、实验结果
见表2~表3和图1。
表2肝微粒体稳定性
表3小鼠体内代谢分析实验
从表2~表3及图1可见,代表化合物I-63具有优异的肝微粒体稳定性;在小鼠体内具有较长的半衰期,较低的清除率。代表化合物I-63的生物利用度较高,AUC也处于合适范围,具有较好的类药性质。
本发明设计的化合物及其药学上可接受的盐具有FGFR抑制作用,可作为药物的有效成分,其制备的药物组合物可以用于制备预防和/或治疗FGFR有关的临床病症的药物,如肝癌、非小细胞肺癌、胃癌、膀胱癌、头颈癌、胆管癌、乳腺癌、子宫内膜癌、***、食道癌、肾癌、急性白血病、***癌、甲状腺癌、皮肤癌、结肠直肠癌、胰腺癌、卵巢癌、骨髓增生异常综合症、间皮瘤等。
Claims (10)
1.一种FGFR抑制剂,其特征在于,具有式I的结构,所述FGFR抑制剂包含其立体异构体、药学上可接受的盐或它们的混合物:
其中,U选自CH或N;
V、W各自独立地选自C或N且不相同;
X选自O、NH、NCH3、NCN或NCF3;
Y选自N或C;
Z选自N或CH;
A环选自芳基或芳杂基;所述芳基选自苯基、萘基、苊基或四氢萘基;所述芳杂基选自哌啶基、吡咯基、吡唑基、咪唑基、呋喃基、噻吩基、噁唑基、异噁唑基、噻唑基、异噻唑基、吡啶基、嘧啶基、吡嗪基、哒嗪基、喹啉基、喹唑啉基、吲哚基、苯并咪唑基、苯并噁唑基、苯并异噁唑基、苯并噻唑基、苯并异噻唑基、苯并呋喃基、苯并噻吩基、2,3-二氢苯并[1,4]二氧杂环己烯基或苯并[1,3]二氧杂环戊烯基;
R1、R2、R3、R4、R6各自独立地选自H、卤素、CH2OH、CF3、OCF3、CN、C1-6烷基或C1-6烷氧基;或者R2、R3连接在一起形成3-8元杂环,所述3-8元杂环任选地被C1-6烷基取代;
R5选自-ORa、-(CH2)mORa、-NRaRb、-CONRaRb、-SO2NRaRb、-(SONH)NRaRb、-(CH2)m-NRaRb、-(CH2)mCON(CH3)2、-(CH2)mSO2N(CH3)2或3-10元杂环,所述3-10元杂环任选地被1-3个R7取代;m=1、2或3;
Ra、Rb各自独立地选自H、C1-6烷基、-COC1-5烷基或-SO2C1-5烷基,所述C1-6烷基、-COC1-5烷基、-SO2C1-5烷基任选地被-NRcRd、-CONRcRd或-SO2C1-5烷基取代;
Rc、Rd各自独立地选自H、C1-6烷基或-COC1-5烷基;
R7选自C1-6烷基、C3-8环烷基、-CONH2、-SO2NH2、-CH2COOH、-CH2SO3H、-CH2CN、-(CH2)2NRcRd、-NRcRd、-(CH2)nOH、-COOC1-6烷基或3-8元杂环,所述3-8元杂环任选地被C1-6烷基取代;n=1、2或3。
2.根据权利要求1所述的FGFR抑制剂,其特征在于,具有式IA或IB的结构:
其中A、X、Y、Z、R1~R6的定义如权利要求1所述。
3.根据权利要求2所述的FGFR抑制剂,其特征在于,所述结构中:
X选自O或NH;
Y选自N或C;
Z选自N或CH;
A环选自芳基或芳杂基;所述芳基选自苯基、萘基、苊基或四氢萘基;所述芳杂基选自哌啶基、吡咯基、吡唑基、咪唑基、呋喃基、噻吩基、噁唑基、异噁唑基、噻唑基、异噻唑基、吡啶基、嘧啶基、吡嗪基、哒嗪基、喹啉基、喹唑啉基、吲哚基、苯并咪唑基、苯并吡唑基、苯并异噁唑基、苯并噻唑基、苯并异噻唑基、苯并呋喃基、苯并噻吩基、2,3-二氢苯并[1,4]二氧杂环己烯基或苯并[1,3]二氧杂环戊烯基;
R1、R2各自独立地选自H、卤素、CN或C1-6烷氧基;
R3、R4各自独立地选自H、卤素、OCF3或C1-6烷氧基;或者R2、R3连接在一起形成5-6元单环烷基或5-6元单环芳杂基;所述5-6元单环烷基选自四氢呋喃基、吡咯烷基、1,3-二噁茂基、1,3-噁唑烷基或哌啶基;所述5-6元单环芳杂基选自哌啶基、吡咯基、吡唑基、咪唑基、呋喃基、噻吩基、噁唑基、异噁唑基、噻唑基、异噻唑基、吡啶基、嘧啶基、吡嗪基或哒嗪基;
R6选自H、卤素、CH2OH、C1-6烷基或C1-6烷氧基;
R5选自-ORa、-(CH2)mORa、-NRaRb、-CONRaRb、-SO2NRaRb、-(SONH)NRaRb、-(CH2)m-NRaRb、-(CH2)mCON(CH3)2、-(CH2)mSO2N(CH3)2或3-10元杂环,所述3-10元杂环任选地被1-3个R7取代;m=1、2或3;
Ra、Rb各自独立地选自H、C1-6烷基、-COC1-5烷基或-SO2C1-5烷基,所述C1-6烷基、-COC1-5烷基、-SO2C1-5烷基任选地被-NRcRd、-CONRcRd或-SO2C1-5烷基取代;
Rc、Rd各自独立地选自H、C1-6烷基或-COC1-5烷基;
R7选自C1-6烷基、C3-8环烷基、-CONH2、-SO2NH2、-CH2COOH、-CH2SO3H、-CH2CN、-(CH2)2NRcRd、-NRcRd、-(CH2)nOH、-COOC1-6烷基或3-8元杂环,所述3-8元杂环任选地被C1-6烷基取代;n=1、2或3。
4.根据权利要求3所述的FGFR抑制剂,其特征在于,所述结构中:
X选自O;
Y选自N或C;
Z选自N或CH;
A环选自苯基、吡唑基、咪唑基、吡啶基、嘧啶基、苯并咪唑基、苯并吡唑基或苯并异噁唑基;
R1、R2各自独立地选自H、F、Cl、CN或C1-3烷氧基;
R3、R4各自独立地选自H、F、Cl或C1-3烷氧基;或者R2、R3连接在一起形成5-6元单环烷基或5-6元单环芳杂基;所述5-6元单环烷基选自1,3-二噁茂基、1,3-噁唑烷基或哌啶基;所述5-6元单环芳杂基选自吡唑基、咪唑基、异噁唑基或噻唑基;
R6选自H、F、Cl或C1-3烷氧基;
R5选自-ORa、-(CH2)mORa、-NRaRb、-CONRaRb、-SO2NRaRb、-(SONH)NRaRb、-(CH2)m-NRaRb、-(CH2)mCON(CH3)2、-(CH2)mSO2N(CH3)2或3-10元杂环,所述3-10元杂环可任选地被1-3个R7取代;m=1、2或3;
Ra、Rb各自独立地选自H、C1-6烷基、-COC1-5烷基或-SO2C1-5烷基,所述C1-6烷基、-COC1-5烷基、-SO2C1-5烷基任选地被-NRcRd、-CONRcRd或-SO2C1-5烷基取代;
Rc、Rd各自独立地选自H、C1-6烷基或-COC1-5烷基;
R7选自C1-6烷基、C3-8环烷基、-CONH2、-SO2NH2、-CH2COOH、-CH2SO3H、-CH2CN、-(CH2)2NRcRd、-NRcRd、-(CH2)nOH、-COOC1-6或3-8元杂环,所述3-8元杂环可任选地被C1-6烷基取代;n=1、2或3。
5.根据权利要求4所述的FGFR抑制剂,其特征在于,所述结构中:
X选自O;
Y选自N或C;
Z选自N或CH;
A环选自苯基、吡唑基、咪唑基、吡啶基、嘧啶基、苯并咪唑基、苯并吡唑基或苯并异噁唑基;
R1、R2各自独立地选自H、F、Cl、CN或C1-3烷氧基;
R3、R4各自独立地选自H、F、Cl或C1-3烷氧基;或者R2、R3连接在一起形成5-6元单环烷基或5-6元单环芳杂基;所述5-6元单环烷基选自1,3-二噁茂基、1,3-噁唑烷基或哌啶基;所述5-6元单环芳杂基选自吡唑基、咪唑基、异噁唑基或噻唑基;
R6选自H、F、Cl或C1-3烷氧基;
R5选自
6.根据权利要求1~5任一所述的FGFR抑制剂,其特征在于,选自下列任一化合物:
N-(4-吗啉苯基)-7-苯磺酰基-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-1),
7-(3-甲氧基苯磺酰基)-N-(4-吗啉苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-2),
N-(4-(4-甲基哌嗪)苯基)-7-(吡啶-3-磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-3),
7-(苯并[d][1,3]二噁茂-5-磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-4),
7-(2-甲氧基苯磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-5),
7-(4-甲氧基苯磺酰基)-N-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-6),
7-(3-氟苯磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-7),
N-(4-(4-甲基哌嗪)苯基)-7-(3-三氟甲基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-8),
7-(3-甲氧基苯磺酰基)-N-(5-(4-甲基哌嗪)吡啶-2-基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-9),
N-(3-甲氧基-4-(4-甲基哌嗪)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-10),
2-(4-(3-甲氧基苯磺酰基)-7H-吡咯并[2,3-d]嘧啶-2-基)氨基)-1H-吡唑基)乙醇(I-11),
7-(2-氟-5-甲氧基苯磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-12),
7-(3-甲氧基苯磺酰基)-N-(6-(4-甲基哌嗪)吡啶-3-基)-7H-吡咯(2,3-d]嘧啶-2-胺(I-13),
1-(1-(4-((7-(3-甲氧基苯磺酰基)-7H-吡咯[2,3-d]嘧啶-2-基)氨基)苯基)哌啶-4-基)-3-甲基氮杂环丁-3-醇(I-14),
N-(4-(4-异丙基哌嗪基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-15),
7-(3-甲氧基苯磺酰基)-N-(4-(1-甲基哌啶-4-基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-16),
7-(3-甲氧基苯磺酰基)-N-(4-(4-(4-(4-(4-甲基哌嗪)哌啶基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-17),
7-(2-甲氧基苯磺酰基)-N-(4-(2-(吡咯烷基)乙氧基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-18),
7-(2,5-二甲氧基苯磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-19),
N-(4-(4-甲基哌嗪)苯基)-7-(3-三氟甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-20),
7-(2-氯苯磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-21),
7-(2,6-二氯苯磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-22),
N-(4-(4-甲基哌嗪)苯基)-7-(2-三氟甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-23),
2-(2-(4-(4-(4-甲基哌嗪)苯基)氨基)-7H-吡咯并[2,3-d]嘧啶-7-磺酰基)苯腈(I-24),
7-(5-氯-2-甲氧基苯磺酰基)-N-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-25),
7-(苯并[d][1,3]二噁茂-4-磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-26),
7-(2,5-二氯苯磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-27),
N-(4-(4-甲基哌嗪)苯基)-7-对甲苯基-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-28),
N-(4-(4-甲基哌嗪)苯基)-7-苯磺酰基-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-29),
7-(3-甲氧基苯磺酰基)-N-(4-((1R)-8-甲基-3,8-二氮杂双环[3.2.1]辛基-3-基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-30),
7-(2,4-二氯吡啶-3-磺酰基)-N-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-31),
N-(3-氟-4-(4-甲基哌嗪)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-32),
7-(3-甲氧基苯磺酰基)-N-(1-(1-甲基哌啶-4-基)-1H-吡唑-4-基)-7H-吡咯醇[2,3-d]嘧啶-2-胺(I-33),
5-(7-甲氧基苯磺酰基)-7H-吡咯并[2,3-d]嘧啶-2-基)氨基)-2-(4-甲基哌嗪)苯酚(I-34),
(5-(((3-甲氧基苯磺酰基)-7H-吡咯嘧啶-2-基)氨基)-2-(4-甲基哌嗪)苯基)甲醇(I-35),
1-(3-甲氧基苯磺酰基)-N-4-(4-甲基哌嗪苯基)-6-氨基-1H-吡咯并[3,2-c]吡啶(I-36),
7-(3-甲氧基苯磺酰基)-N-(4-(4-(四羟基-2H-吡喃-4-基)哌嗪基)苯基)-7H-吡咯(2,3-d]嘧啶-2-胺(I-37),
7-(3-甲氧基苯磺酰基)-N-(4-(4-硫代哌啶基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-38),
7-(3-甲氧基苯磺酰基)-N-(4-(4-(1-(1-甲基哌啶-4-基)哌嗪基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-39),
7-(3-甲氧基苯磺酰基)-N-(4-((1S4S)-5-甲基-2,5-二氮杂双环[2.2.1]庚烷-2-基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-40),
7-(3-甲氧基苯磺酰基)-N-(4-甲基哌嗪)-3-((四氢呋喃-3-基)氧基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-41),
N-(3-异丙氧基-4-(4-甲基哌嗪)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-42),
N-(4-((3R,5R)-3,5-二甲基哌嗪基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-43),
N-(4-(二甲基氨基)吡咯烷基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-44),
N-(4-(二甲基氨基)哌啶基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-45),
7-(2,3-二甲氧基苯磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-46),
7-(3-甲氧基苯磺酰基)-N-(4-甲基哌嗪)-3-(2-吗啉乙氧基)苯基)-7H-吡咯嘧啶-2-胺(I-47),
N-(2-(二甲基氨基)乙基)-1H-吲唑-5-基)-7-(3-甲氧基苯磺酰基)-7H-吡咯((3-甲氧基苯基)[2,3-d]嘧啶-2-胺(I-48),
N-(2-(二甲基氨基)乙基)-1H-吲唑-6-基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-49),
7-(3,5-二氟苯磺酰基)-N-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-50),
7-(2-氯-5-甲氧基苯磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-51),
7-(3,5-二氟-2-甲氧基苯磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-52),
7-(3-甲氧基苯磺酰基)-N-(3-甲基-4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-53),
N-(4-乙基哌嗪基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-54),
N-(3-氯-4-(4-甲基哌嗪)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-55),
7-(3-甲氧基苯磺酰基)-N-(4-((((1-甲基哌啶-4-基)氧基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-56),
N-(2-(二甲基氨基)乙基)-1H-吡唑-4-基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-57),
N-(1-(二甲基氨基)丙基)-1H-吡唑-4-基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-58),
2-(4-(4-((7-(3-甲氧基苯磺酰基)-7H-吡咯并[2,3-d]嘧啶-2-基)氨基)苯基)哌嗪基)乙醇(I-59),
(4-((7-(3-甲氧基苯磺酰基)-7H-吡咯并[2,3-d]嘧啶-2-基)氨基)苯基)(4-甲基哌嗪-1)甲酮(I-60),
7-(3-甲氧基苯磺酰基)-N-(4-((3aR,6aS)-5-甲基六氢吡咯并[3,4-c]吡咯-2(1H)-基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-61),
7-(3-甲氧基苯磺酰基)-N-(4-((4-甲基哌嗪)甲基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-62),
N-(4-((3S,5R)-3,5-二甲基哌嗪基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-63),
7-(3-甲氧基苯磺酰基)-N-(4-(4-甲基哌嗪苯基))-2-氨基吡咯并[2,1-f][1,2,4]三嗪(I-64),
7-(3-甲氧基苯磺酰基)-N-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-65),
N-(4-(2,7-二氮杂物[3.5]壬烯-7-基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-66),
7-(5-异丙基吡啶-3-磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-67),
7-(3-甲氧基苯磺酰基)-N-(4-(2-甲基-2,7-二氮杂螺[3.5]壬烯-7-基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-68),
7-(5-甲氧基吡啶-3-磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-69),
N-(4-((1S,4S)-2,5-二氮杂双环[2.2.1]庚烷-2-基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-70),
7-(5-氟吡啶-3-磺酰基)-N-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-71),
N-(((1R,4R)-2,5-二氮杂双环[2.2.1]庚烷-2-基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-72),
7-(4-甲氧基吡啶-3-磺酰基)-N-(4-(4-甲基哌嗪)苯基)-7H-吡咯并[2,3-d]嘧啶-2胺(I-73),
7-(3-甲氧基苯磺酰基)-N-(4-((1R4R)-5-甲基-2,5-二氮杂双环[2.2.1]庚烷-2-基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-74),
1-(4-((7-(3-甲氧基苯磺酰基)-7H-吡咯并[2,3-d]嘧啶-2-基)氨基)苯基)-4-甲基-2-哌嗪酮(I-75),
7-(3-甲氧基苯磺酰基)-N-(4-((1S,4S)-5-甲基-2,5-二氮杂双环[2.2.1]庚烷-2-基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-76),
7-(2-氯-3-甲氧基苯磺酰基)-N-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-77),
N-(4-((1R)-3,8-二氮杂双环[3.2.1]辛烷-3-基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-78),
7-(3-氟-5-甲氧基苯磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-79),
1-(4-(4-((7-(3-甲氧基苯磺酰基)-7H-吡咯并[2,3-d]嘧啶-2-基)氨基)苯基)哌嗪基)乙酮(I-80),
7-(2,6-二氯-3-氟-5-甲氧基苯磺酰基)-N-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-81),
N-(4-环丙基哌嗪基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-82),
7-(2,6-二氯-3-甲氧基苯磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-83),
7-(3-甲氧基苯磺酰基)-N-(4-甲基-2,7-二氮杂螺[3.5]壬二酰基-2-基)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-84),
7-(2,4-二氯-5-甲氧基吡啶-3-磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-85),
N-(4-(2,7-二氮杂螺[3.5]壬烯-2-基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-86),
7-(2,4-二氯-5-氟吡啶-3-磺酰基)-N-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-87),
4-(4-(3-甲氧基苯磺酰基)-7H-吡咯并[2,3-d]嘧啶-2-基)氨基)苯基)-2-哌嗪酮(I-88),
7-(2-甲氧基吡啶-3-磺酰基)-N-(4-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-89),
N-(4-((3S,5S)-3,5-二甲基哌嗪基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-90),
7-(4-氯吡啶-3-磺酰基)-N-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-91),
N-(4-((3S,5S)-3,5-二甲基哌嗪基)苯基)-7-(3-甲氧基苯磺酰基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-92),
7-(2-氯吡啶-3-磺酰基)-N-(4-甲基哌嗪)苯基)-2-氨基-7H-吡咯并[2,3-d]嘧啶(I-93),
1-亚氨基-4-(4-((7-(3-甲氧基苯磺酰基)-7H-吡咯并[2,3-d]嘧啶-2-基)氨基)苯基)-硫代吗啉-1-氧化物(I-94)。
7.根据权利要求1~5任一所述的FGFR抑制剂,其特征在于,所述药学上可接受的盐包括通式I化合物与下列酸形成的盐:盐酸、氢溴酸、硫酸、磷酸、甲磺酸、苯磺酸、对甲苯磺酸、萘磺酸、拧檬酸、酒石酸、乳酸、丙酮酸、乙酸、马来酸或琥珀酸、富马酸、水杨酸、苯基乙酸、杏仁酸;还包括通式I化合物与下列碱形成的盐:碱性金属阳离子盐、碱土金属阳离子盐或铵阳离子盐。
8.一种权利要求1~7任一所述的FGFR抑制剂的制备方法,其特征在于:选自下列任一方法:
(1)当U、W为N,V为C时,以溴代苯或溴代吡啶为起始原料,经过取代、卤代、酰化反应制备而成通式化合物IA,
(2)当U、W为N,V为C时,以溴代苯或溴代吡啶为起始原料,经过取代、卤代、酰化、取代反应制备而成通式化合物IA,
(3)当U、V为N,W为C时,卤代吡咯并[2,1-f][1,2,4]三嗪为起始原料,经过两步取代、氧化、反应制备而成通式化合物IB,
其中,Y、Z、R1~R6的定义如权利要求1~6任一所述;
将上述方法制备而成的化合物IA或IB与相应的酸或碱成盐,即得其药学上可接受的盐。
9.一种药物组合物,其特征在于,包括权利要求1~7任一所述的FGFR抑制剂以及药学上可接受的载体。
10.一种权利要求1~7任一所述的FGFR抑制剂或者权利要求9所述的药物组合物在制备预防和/或治疗FGFR相关疾病药物中的应用,所述FGFR相关疾病选自肝癌、非小细胞肺癌、胃癌、膀胱癌、头颈癌、胆管癌、乳腺癌、子宫内膜癌、***、食道癌、肾癌、急性白血病、***癌、甲状腺癌、皮肤癌、结肠直肠癌、胰腺癌、卵巢癌、骨髓增生异常综合症或间皮瘤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210667176.7A CN117263940A (zh) | 2022-06-14 | 2022-06-14 | Fgfr抑制剂及其制备方法、药物组合物和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210667176.7A CN117263940A (zh) | 2022-06-14 | 2022-06-14 | Fgfr抑制剂及其制备方法、药物组合物和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117263940A true CN117263940A (zh) | 2023-12-22 |
Family
ID=89220131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210667176.7A Pending CN117263940A (zh) | 2022-06-14 | 2022-06-14 | Fgfr抑制剂及其制备方法、药物组合物和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117263940A (zh) |
-
2022
- 2022-06-14 CN CN202210667176.7A patent/CN117263940A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI824405B (zh) | 四環氧氮呯化合物及其用途 | |
KR101961500B1 (ko) | 세린/트레오닌 키나제 억제제 | |
KR20200119824A (ko) | 축합 고리 화합물 | |
CN115873020A (zh) | Ras抑制剂 | |
CN116457358A (zh) | 作为ras抑制剂以治疗癌症的吲哚衍生物 | |
JP6035423B2 (ja) | 新規な縮合ピリミジン化合物又はその塩 | |
IL291901A (en) | Bicyclyl heterocycles as fgr suppressors | |
US9796725B2 (en) | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | |
WO2015158310A1 (zh) | 一种酪氨酸激酶抑制剂及其用途 | |
US20190151330A1 (en) | Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | |
RU2643361C2 (ru) | Новые производные триазолопиразина и их применение | |
CN116323623A (zh) | 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺 | |
TW201605867A (zh) | 噻吩并嘧啶 | |
CN108349896A (zh) | 作为fgfr抑制剂的杂环化合物 | |
CA3200620A1 (en) | Aromatic heterocyclic compound, and pharmaceutical composition and application thereof | |
CN113631557A (zh) | Jak激酶抑制剂及其制备方法和在医药领域的应用 | |
CN116113633A (zh) | 一种作为可透脑的btk或her2抑制剂的化合物及其制备方法与用途 | |
TW202400601A (zh) | 作為parp抑製劑的取代的三環類化合物及其用途 | |
CN111094292A (zh) | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 | |
CN110036012A (zh) | 吡啶并[3,4-d]嘧啶衍生物及其药学上可接受的盐 | |
CN112585138A (zh) | 可用于治疗癌症的作为ErbB调节剂的4-取代的吡咯并[2,3-b]吡啶 | |
CN114380806B (zh) | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 | |
CN117263940A (zh) | Fgfr抑制剂及其制备方法、药物组合物和应用 | |
CN115677772A (zh) | 一种用于egfr激酶抑制剂的化合物、组合物及其应用 | |
TW202317574A (zh) | Cdk2抑制劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |